RESUMEN
Citalopram, an antidepressant drug have been detected in different environmental matrices due to its high consumption. Previous study has proved that citalopram may alter the behaviour of aquatic organisms at environmentally relevant concentrations. However, scientific knowledge is still lacking on the ecotoxicological effects of citalopram on aquatic organisms. For this reason, the present study is aimed to investigate the potential toxicity of citalopram in terms of development, antioxidant, neurotoxicity, apoptosis, lipogenesis, and bone mineralization in embryonic and larval zebrafish (Danio rerio) at environmentally relevant concentrations. We noticed that citalopram exposure at 1 and 10 µg/L concentration delays hatching and heartbeat at 24, 48, 72 and 96 hpf. Exposure to citalopram also significantly increased mortality at 10 µg/L. Abnormal development with yolk sac edema, pericardial edema and scoliosis were also observed after citalopram treatment. In addition, citalopram significantly (P < 0.001) induced superoxide dismutase (SOD), catalase (CAT), glutathione-S-transferase (GST) and lipid peroxidation (LPO) levels. A significant decrease in acetylcholine esterase (AChE) activity was also observed in citalopram exposed groups. We found significant dose-and time-dependent increases in apoptosis, lipogenesis, and bone mineralization. In conclusion, the findings of the present study can provide new insights on the ecotoxicity of citalopram in the aquatic environment.
Asunto(s)
Citalopram , Contaminantes Químicos del Agua , Pez Cebra , Animales , Pez Cebra/embriología , Citalopram/toxicidad , Contaminantes Químicos del Agua/toxicidad , Superóxido Dismutasa/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Catalasa/metabolismo , Glutatión Transferasa/metabolismo , Embrión no Mamífero/efectos de los fármacos , Larva/efectos de los fármacos , Larva/crecimiento & desarrollo , Antioxidantes/metabolismo , Estrés Oxidativo/efectos de los fármacosRESUMEN
Pharmaceuticals have been classified as an environmental concern due to their increasing consumption globally and potential environmental impact. We examined the toxicity of sediment-associated diclofenac and citalopram administered as both single compounds and in a mixture to the sediment-living amphipod Corophium volutator. This laboratory-based study addressed the following research questions: (1) What is the toxicity of sediment-associated diclofenac and citalopram to C. volutator? (2) Can the mixture effect be described with either of the two mixture models: concentration addition (CA) or independent action (IA)? (3) What is the importance of the choice of (i) exposure measure (start concentration, time-weighted average [TWA], full exposure profile) and (ii) effect model (concentration-response vs. the toxicokinetic-toxicodynamic model general unified threshold model for survival in its reduced form [GUTS-RED]) for the derived effect concentration values? Diclofenac was more toxic than citalopram to C. volutator as a single compound (10-day exposure). Diclofenac exposure to C. volutator provided median lethal concentrations (LC50s) within the same range (11 µg g-1 dry wt sediment) using concentration-response based on TWA and both GUTS-RED models. However, concentration-response based on measured start concentrations provided an approximately 90% higher LC50 (21.6 ± 2.0 µg g-1 dry wt sediment). For citalopram, concentration-response parameters were similar regardless of model or concentration used (LC50 85-97 µg g-1 dry wt sediment), however, GUTS-RED with the assumption of individual tolerance resulted in a lower LC50 (64.9 [55.3-74.8] µg g-1 dry wt sediment). The mixture of diclofenac and citalopram followed the CA quite closely, whereas the result was synergistic when using the IA prediction. In summary, concentration-response based on TWA and GUTS-RED provided similar and reasonably good fits compared to the data set. The implications are that GUTS-RED will provide a more flexible model, which, in principle, can extend beyond the experimental period and make predictions based on variable exposure profiles (toxicity at different time frames and at different variable exposure scenarios) compared to concentration-response, which provides contaminant toxicity at one point in time. Environ Toxicol Chem 2024;43:1767-1777. © 2024 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.
Asunto(s)
Anfípodos , Citalopram , Diclofenaco , Sedimentos Geológicos , Contaminantes Químicos del Agua , Anfípodos/efectos de los fármacos , Animales , Sedimentos Geológicos/química , Diclofenaco/toxicidad , Contaminantes Químicos del Agua/toxicidad , Citalopram/toxicidad , Relación Dosis-Respuesta a DrogaRESUMEN
St. John's Wort preparations are used for the treatment of mild to moderate depression. They are usually well tolerated but can cause adverse reactions including liver toxicity in rare cases. To date, the mechanism(s) underlying the hepatotoxicity of St. John's Wort extracts are poorly investigated. We studied the hepatocellular toxicity of hypericin and hyperforin as the two main ingredients of St. John's Wort extracts in HepG2 and HepaRG cells and compared the effects to citalopram (a synthetic serotonin uptake inhibitor) with a special focus on mitochondrial toxicity and oxidative stress. In HepG2 cells, hypericin was membrane-toxic at 100 µM and depleted ATP at 20 µM. In HepaRG cells, ATP depletion started at 5 µM. In comparison, hyperforin and citalopram were not toxic up to 100 µM. In HepG2 cells, hypericin decreased maximal respiration starting at 2 µM and mitochondrial ATP formation starting at 10 µM but did not affect glycolytic ATP production. Hypericin inhibited the activity of complex I, II and IV of the electron transfer system and caused mitochondrial superoxide accumulation in cells. The protein expression of mitochondrial superoxide dismutase 2 (SOD2) and thioredoxin 2 (TRX2) and total and reduced glutathione decreased in cells exposed to hypericin. Finally, hypericin diminished the mitochondrial DNA copy number and caused cell necrosis but not apoptosis. In conclusion, hypericin, but not hyperforin or citalopram, is a mitochondrial toxicant at low micromolar concentrations. This mechanism may contribute to the hepatotoxicity occasionally observed in susceptible patients treated with St. John's Wort preparations.
Asunto(s)
Antracenos , Carcinoma Hepatocelular , Enfermedad Hepática Inducida por Sustancias y Drogas , Hypericum , Neoplasias Hepáticas , Perileno/análogos & derivados , Floroglucinol/análogos & derivados , Terpenos , Humanos , Extractos Vegetales/toxicidad , Extractos Vegetales/uso terapéutico , Hypericum/toxicidad , Citalopram/toxicidad , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Adenosina TrifosfatoRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Adulto , Suplementos Dietéticos , Citalopram/toxicidad , Intoxicación/tratamiento farmacológico , Agitación Psicomotora/complicaciones , Rigidez Muscular/complicaciones , Hemodiafiltración/métodosRESUMEN
Las alertas generadas por las agencias reguladoras acerca de la posible toxicidad cardíaca del citalopram y el escitalopram han generado alarma entre los clínicos prescriptores. La revisión de los datos acerca de la mencionada toxicidad evidencia que debe limitarse a pacientes con historia clínica de síncopes o en casos de intoxicación. Como medida de precaución debería introducirse la realización de un electrocardiograma en pacientes de edad avanzada (AU)
The alerts issued by regulatory agencies on the potential cardiac toxicity of citalopram and escitalopram have caused alarm among clinicians. A review of the data concerning this topic shows that the alarm should be limited to patients with a history of syncope or poisoning. As a precautionary measure, an electrocardiogram should be performed on elderly patients (AU)
Asunto(s)
Humanos , Masculino , Femenino , Síndrome de QT Prolongado/complicaciones , Síndrome de QT Prolongado/tratamiento farmacológico , Citalopram/efectos adversos , Citalopram/toxicidad , /complicaciones , Enfermedades Cardiovasculares/inducido químicamente , Enfermedades Cardiovasculares/complicaciones , Enfermedades Cardiovasculares/prevención & control , Síndrome de QT Prolongado/patología , Síndrome de QT Prolongado/prevención & control , Síndrome de QT Prolongado , Citalopram/administración & dosificación , Arritmias Cardíacas/complicaciones , Cardiopatías/inducido químicamente , Cardiopatías/complicaciones , FarmacovigilanciaRESUMEN
No disponible